Neuronascent to Present New Parkinson™s Model Data at AAIC 2023 for NNI-362
28 Jun 2023 //
GLOBENEWSWIRE
Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022
08 Nov 2022 //
GLOBENEWSWIRE
Neuronascent Receives FDA ODD for NNI-351 Treatment of Fragile X Syndrome
01 Jun 2022 //
GLOBENEWSWIRE
Neuronascent Receives FDA RPD Designation for NNI-351 for Fragile X Syndrome
24 May 2022 //
GLOBENEWSWIRE
Neuronascent Releases Further Positive Results of NNI-362 in Phase 1a Trial
30 Mar 2022 //
GLOBENEWSWIRE